<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402102</url>
  </required_header>
  <id_info>
    <org_study_id>Doul-BGarlic-001</org_study_id>
    <nct_id>NCT01402102</nct_id>
  </id_info>
  <brief_title>A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia</brief_title>
  <official_title>Efficacy and Safety of Aged Garlic Powder on Lipids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We performed a double-blind parallel study in a group of mildly hypercholesterolemic subjects
      who were given aged garlic powder over a period of 12 weeks. We measured serum lipids,
      including total cholesterol, low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL)
      cholesterol, and triglycerides, and monitored their blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An increased serum cholesterol level is an important risk factor for the development of
      cardiovascular and cerebrovascular disease. Reduction of these and other risk factors through
      dietary modification, behavioral changes, and medicinal intervention has already
      substantially decreased the incidence and mortality from cardiovascular and cerebrovascular
      disease. Supplementation of the diet with certain biofactors may further reduce such risk
      factors. Aged garlic belongs to a group of dietary supplements that may lessen the incidence
      of cardiovascular and cerebrovascular disease by reducing lipids levels and decreasing
      platelet responsiveness to activating agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in LDL-cholesterol(Low Density Lipoprotein - Cholesterol)</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL-C(Low Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL-Cholesterol(High Density Lipoprotein - Cholesterol)</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL-cholesterol(High Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglyceride was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Apo-A1(Apolipoprotein A1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Apo-A1(Apolipoprotein A1) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Apo-B(Apolipoprotein B)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Apo-B(Apolipoprotein B) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FFA(Free Fatty Acid)</measure>
    <time_frame>12 weeks</time_frame>
    <description>FFA(free fatty acid) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Aged garlic powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aged garlic powder</intervention_name>
    <description>Aged garlic powder(6.0g/day)</description>
    <arm_group_label>Aged garlic powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo powder</intervention_name>
    <description>Placebo powder(6.0g/day)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild hypercholesterolemic subjects aged from 20 to 80 years

          -  had no received lipid-lowering drugs for at least 3 months prior to the recruitment

        Exclusion Criteria:

          -  self-reported pregnancy,lactation

          -  prevalent heart disease,cancer,renal disorder, or diabetes mellitus, and use of lipid
             or antihypertensive medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dal-Sik Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2012</results_first_posted>
  <last_update_submitted>October 11, 2012</last_update_submitted>
  <last_update_submitted_qc>October 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Aged garlic</keyword>
  <keyword>Hyperlipidemic</keyword>
  <keyword>LDL</keyword>
  <keyword>HDL</keyword>
  <keyword>Triglyceride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 20 to 80 years, a BMI(Body Mass Index)&gt;23 kg/m^2, an LDL-C(Low Density Lipoprotein-cholesterol) concentration between 130 and 220 mg/dL. Subjects were excluded if they had heart disease, liver or kidney disease, irregular lifestyle habits, or if they took medication and functional foods known to affect lipid metabolism</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aged Garlic Powder</title>
          <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral intake placebo(6.0g/day) for 12weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficiency of compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aged Garlic Powder</title>
          <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral intake placebo(6.0g/day) for 12weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="9.2"/>
                    <measurement group_id="B2" value="50.8" spread="8"/>
                    <measurement group_id="B3" value="50.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in LDL-cholesterol(Low Density Lipoprotein - Cholesterol)</title>
        <description>LDL-C(Low Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(6.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in LDL-cholesterol(Low Density Lipoprotein - Cholesterol)</title>
          <description>LDL-C(Low Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.6" spread="14.1"/>
                    <measurement group_id="O2" value="150.1" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.8" spread="21.9"/>
                    <measurement group_id="O2" value="156.3" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in HDL-Cholesterol(High Density Lipoprotein - Cholesterol)</title>
        <description>HDL-cholesterol(High Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>PP analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Aged garlic powder 6.0g/day oral intake</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 6.0g/day oral intake</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in HDL-Cholesterol(High Density Lipoprotein - Cholesterol)</title>
          <description>HDL-cholesterol(High Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>PP analysis</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" spread="9.40"/>
                    <measurement group_id="O2" value="50.81" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.36" spread="8.85"/>
                    <measurement group_id="O2" value="50.48" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Triglycerides</title>
        <description>Triglyceride was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>PP analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Aged garlic powder 6.0g/day oral intake</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 6.0g/day oral intake</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Triglycerides</title>
          <description>Triglyceride was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>PP analysis</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.79" spread="54.55"/>
                    <measurement group_id="O2" value="124.11" spread="47.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.21" spread="63.61"/>
                    <measurement group_id="O2" value="128.11" spread="65.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Cholesterol</title>
        <description>Total cholesterol was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(6.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Cholesterol</title>
          <description>Total cholesterol was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.07" spread="23.97"/>
                    <measurement group_id="O2" value="228.93" spread="20.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.50" spread="24.63"/>
                    <measurement group_id="O2" value="227.33" spread="32.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Apo-A1(Apolipoprotein A1)</title>
        <description>Apo-A1(Apolipoprotein A1) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(6.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Apo-A1(Apolipoprotein A1)</title>
          <description>Apo-A1(Apolipoprotein A1) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.21"/>
                    <measurement group_id="O2" value="1.43" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.19"/>
                    <measurement group_id="O2" value="1.39" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Apo-B(Apolipoprotein B)</title>
        <description>Apo-B(Apolipoprotein B) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(6.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Apo-B(Apolipoprotein B)</title>
          <description>Apo-B(Apolipoprotein B) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.13"/>
                    <measurement group_id="O2" value="1.03" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.12"/>
                    <measurement group_id="O2" value="1.01" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in FFA(Free Fatty Acid)</title>
        <description>FFA(free fatty acid) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Powder</title>
            <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(6.0g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in FFA(Free Fatty Acid)</title>
          <description>FFA(free fatty acid) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>ÂµEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570.25" spread="193.02"/>
                    <measurement group_id="O2" value="554.04" spread="179.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="618.14" spread="184.78"/>
                    <measurement group_id="O2" value="523.93" spread="222.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Aged Garlic Powder</title>
          <description>Oral intake Aged garlic powder(6.0g/day) for 12weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral intake placebo(6.0g/day) for 12weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dal-Sik Kim</name_or_title>
      <organization>Clinical trial center for Functional Food in Chonbuk Nat'l University Hospital</organization>
      <phone>82-63-250-1793</phone>
      <email>dskim@chonbuk.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

